rituximab   Click here for help

GtoPdb Ligand ID: 6780

Synonyms: HSDB 7455 | IDEC-C2B8 | MabThera® | Rituxan®
Approved drug Immunopharmacology Ligand
rituximab is an approved drug (FDA (1997), EMA (1998))
Compound class: Antibody
Comment: Rituximab is a type I anti-CD20 monoclonal, designed to target surface CD20 on B-lymphocytes. It is a cancer and autoimmune disease drug.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

NameTrade nameCompanyClinical PhaseIndications
CT-P10; rituximab-abbsBlitzima; Truxima; Tuxella (renamed Rituenza); RitemviaCelltrionApproved (EMA 2017, FDA 2018)Non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and severe rheumatoid arthritis (Truxima only). Rituenza's marketing authorisation withdrawn in EU in 2017 at Celltrion's request.
PF-05280586; rituximab-pvvrRuxience PfizerApproved (FDA 2019, EMA 2020)NHL, CLL, GPA, MPA
BCD-020AcellBiaBiocadApproved in 2014 by the Ministry of Health of the Russian Federation; Ph 3 trials elsewhere- see NCT02744196 and NCT01759030 as examplesRheumatoid arthritis
GP2013Rixathon; RiximyoSandozApproved (EMA 2017) NHL, CLL
SAIT101 Archigen BiotechPh 3 comparision clinical trial with MabThera® for follicular lymphoma (NCT02809053), and Ph 1 NCT02819726 for rheumatoid arthritisRheumatoid arthritis, follicular lymphoma
rituximab-arrx; ABP 798RiabniAmgenApproved (FDA 2020)NHL, CLL, GPA (Wegener's granulomatosis), and MPA
rituximab; RTXM83-MB01; RTXM-83Novex; RigetuxermAbxienceApproved (Brazil 2019; and other Latin American countries)NHL
zuberitamab; HS006Enrexib, AnruixiZhejiang Hisun PharmaceuticaApproved (China NMPA 2023)CD20-positive diffuse large B-cell lymphoma
BI 695500 Boehringer IngelheimDevelopment halted at Ph 3 (NCT02417129)NHL
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rituximab

Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (1997), EMA (1998))
WHO Essential Medicine WHO Essential Medicines List (EML) (23rd List, 2023). Access PDF version.
Click to view more information about the WHO Model Lists of Essential Medicines.
International Nonproprietary Names Click here for help
INN number INN
7609 rituximab
Synonyms Click here for help
HSDB 7455 | IDEC-C2B8 | MabThera® | Rituxan®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 161
Other databases
GtoPdb PubChem SID 178103386
Immunopaedia Search rituximab
PubChem SID 178103386
Search PubMed clinical trials rituximab
Search PubMed titles rituximab
Search PubMed titles/abstracts rituximab
Wikipedia Rituximab